Tracking human multiple myeloma xenografts in NOD-Rag-1/IL-2 receptor gamma chain-null mice with the novel biomarker AKAP-4

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Mirandola, Leonardo ^a,b   Yu, Yuefei ^a   Jenkins, Marjorie R ^a,b   Chiaramonte, Raffaella ^a,c   Cobos, Everardo ^a,b   John, Constance M ^d   Chiriva Internati, Maurizio ^a,b  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF MILAN   (Italy)

^d MandalMed Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AKAP 4 ANTIGEN; BIOLOGICAL MARKER; CD38 ANTIGEN; CD45 ANTIGEN; MESSENGER RNA; PARAPROTEIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; AKAP4 PROTEIN, MOUSE; CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN; HOMEODOMAIN PROTEIN; INTERLEUKIN 2 RECEPTOR GAMMA; RAG 1 PROTEIN; RAG-1 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER LOCALIZATION; CELL ASSAY; CELL SPREADING; CELL TRACKING; CONTROLLED STUDY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PROTEIN EXPRESSION; TUMOR XENOGRAFT; VALIDATION PROCESS; ANIMAL; CELL PROLIFERATION; DISEASE MODEL; FEMALE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOPHENOTYPING; METABOLISM; MOUSE MUTANT; NONOBESE DIABETIC MOUSE; TUMOR CELL LINE;

A KINASE ANCHOR PROTEINS; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOPHENOTYPING; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; MICE; MICE, INBRED NOD; MICE, KNOCKOUT; MULTIPLE MYELOMA; RNA, MESSENGER;

EID: 80052857421     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-394     Document Type: Article

References (78)

1. Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J, Howlader N, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Cronin K, Chen HS, Feuer EJ, Stinchcomb DG, Edwards BK, . eds SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. Bethesda MD, eds.
2. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson DR, Plevak ME, Therneau TM, Greipp PR. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003, 78(1):21-33. 10.4065/78.1.21, 12528874.
3. Lonial S, Cavenagh J. Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma. Br J Haematol 2009, 145(6):681-708. 10.1111/j.1365-2141.2009.07649.x, 19344388.
4. Kastritis E, Zervas K, Symeonidis A, Terpos E, Delimbassi S, Anagnostopoulos N, Michali E, Zomas A, Katodritou E, Gika D, Pouli A, Christoulas D, Roussou M, Kartasis Z, Economopoulos T, Dimopoulos MA. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). Leukemia 2009, 23(6):1152-1157. 10.1038/leu.2008.402, 19225533.
5. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR, Kyle RA, Gertz MA. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008, 111(5):2516-2520. 10.1182/blood-2007-10-116129, 2254544, 17975015.
6. Harousseau JL. Ten years of improvement in the management of multiple myeloma: 2000-2010. Clin Lymphoma Myeloma Leuk 2010, 10(6):424-442. 10.3816/CLML.2010.n.076, 21156460.
7. Harousseau JL, Attal M, Avet-Loiseau H. The role of complete response in multiple myeloma. Blood 2009, 114(15):3139-3146. 10.1182/blood-2009-03-201053, 19638622.
8. Bankert RB, Hess SD, Egilmez NK. SCID mouse models to study human cancer pathogenesis and approaches to therapy: potential, limitations, and future directions. Front Biosci 2002, 1(7):c44-62.
9. Dalton W, Anderson KC. Synopsis of a roundtable on validating novel therapeutics for multiple myeloma. Clin Cancer Res 2006, 12(22):6603-6610. 10.1158/1078-0432.CCR-06-1489, 17121878.
10. Epstein J, Yaccoby S. The SCID-hu myeloma model. Methods Mol Med 2005, 113:183-190.
11. Mitsiades CS, Anderson KC, Carrasco DR. Mouse models of human myeloma. Hematol Oncol Clin North Am 2007, 21(6):1051-1069. 10.1016/j.hoc.2007.08.003, 17996588.
12. Podar K, Tai YT, Hideshima T, Vallet S, Richardson PG, Anderson KC. Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs 2009, 14(1):99-127. 10.1517/14728210802676278, 19249983.
13. Cocco C, Giuliani N, Di Carlo E, Ognio E, Storti P, Abeltino M, Sorrentino C, Ponzoni M, Ribatti D, Airoldi I. Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma. Clin Cancer Res 2010, 16(16):4188-4197. 10.1158/1078-0432.CCR-10-0173, 20587591.
14. Dai Y, Chen S, Shah R, Pei XY, Wang L, Almenara JA, Kramer LB, Dent P, Grant S. Disruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo. Blood 2011, 117(6):1947-1957. 10.1182/blood-2010-06-291146, 21148814.
15. Manohar SM, Rathos MJ, Sonawane V, Rao SV, Joshi KS. Cyclin-dependent kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription. Leuk Res 2011, 7:7.
16. de Brito LR, Batey MA, Zhao Y, Squires MS, Maitland H, Leung HY, Hall AG, Jackson G, Newell DR, Irving JA. Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma. Leuk Res 2011, 10:10.
17. Li J, Favata M, Kelley JA, Caulder E, Thomas B, Wen X, Sparks RB, Arvanitis A, Rogers JD, Combs AP, Vaddi K, Solomon KA, Scherle PA, Newton R, Fridman JS. INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support. Neoplasia 2010, 12(1):28-38. 2805881, 20072651.
18. Tong AW, Huang YW, Zhang BQ, Netto G, Vitetta ES, Stone MJ. Heterotransplantation of human multiple myeloma cell lines in severe combined immunodeficiency (SCID) mice. Anticancer Res 1993, 13(3):593-597.
19. LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mitsiades N, Neuberg D, Goloubeva O, Pien CS, Adams J, Gupta D, Richardson PG, Munshi NC, Anderson KC. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002, 62(17):4996-5000.
20. Podar K, Tonon G, Sattler M, Tai YT, Legouill S, Yasui H, Ishitsuka K, Kumar S, Kumar R, Pandite LN, Hideshima T, Chauhan D, Anderson KC. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc Natl Acad Sci USA 2006, 103(51):19478-19483. 10.1073/pnas.0609329103, 1748251, 17164332.
21. Navas TA, Nguyen AN, Hideshima T, Reddy M, Ma JY, Haghnazari E, Henson M, Stebbins EG, Kerr I, O'Young G, Kapoun AM, Chakravarty S, Mavunkel B, Perumattam J, Luedtke G, Dugar S, Medicherla S, Protter AA, Schreiner GF, Anderson KC, Higgins LS. Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo. Leukemia 2006, 20(6):1017-1027. 10.1038/sj.leu.2404200, 16617327.
22. Carlo-Stella C, Guidetti A, Di Nicola M, Longoni P, Cleris L, Lavazza C, Milanesi M, Milani R, Carrabba M, Farina L, Formelli F, Gianni AM, Corradini P. CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice. Exp Hematol 2006, 34(6):721-727. 10.1016/j.exphem.2006.03.005, 16728276.
23. Baughn LB, Di Liberto M, Wu K, Toogood PL, Louie T, Gottschalk R, Niesvizky R, Cho H, Ely S, Moore MA, Chen-Kiang S. A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer Res 2006, 66(15):7661-7667. 10.1158/0008-5472.CAN-06-1098, 16885367.
24. Watanabe M, Dewan MZ, Okamura T, Sasaki M, Itoh K, Higashihara M, Mizoguchi H, Honda M, Sata T, Watanabe T, Yamamoto N, Umezawa K, Horie R. A novel NF-kappaB inhibitor DHMEQ selectively targets constitutive NF-kappaB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo. Int J Cancer 2005, 114(1):32-38. 10.1002/ijc.20688, 15523684.
25. Dewan MZ, Watanabe M, Terashima K, Aoki M, Sata T, Honda M, Ito M, Yamaoka S, Watanabe T, Horie R, Yamamoto N. Prompt tumor formation and maintenance of constitutive NF-kappaB activity of multiple myeloma cells in NOD/SCID/gammacnull mice. Cancer Sci 2004, 95(7):564-568. 10.1111/j.1349-7006.2004.tb02487.x, 15245591.
26. Pearson T, Shultz LD, Miller D, King M, Laning J, Fodor W, Cuthbert A, Burzenski L, Gott B, Lyons B, Foreman O, Rossini AA, Greiner DL. Non-obese diabetic-recombination activating gene-1 (NOD-Rag1 null) interleukin (IL)-2 receptor common gamma chain (IL2r gamma null) null mice: a radioresistant model for human lymphohaematopoietic engraftment. Clin Exp Immunol 2008, 154(2):270-284. 10.1111/j.1365-2249.2008.03753.x, 2612717, 18785974.
27. Mitsiades CS, Mitsiades NS, Bronson RT, Chauhan D, Munshi N, Treon SP, Maxwell CA, Pilarski L, Hideshima T, Hoffman RM, Anderson KC. Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications. Cancer Res 2003, 63(20):6689-6696.
28. Asosingh K, De Raeve H, Van Riet I, Van Camp B, Vanderkerken K. Multiple myeloma tumor progression in the 5T2MM murine model is a multistage and dynamic process of differentiation, proliferation, invasion, and apoptosis. Blood 2003, 101(8):3136-3141. 10.1182/blood-2002-10-3000, 12480692.
29. Chantry AD, Heath D, Mulivor AW, Pearsall S, Baud'huin M, Coulton L, Evans H, Abdul N, Werner ED, Bouxsein ML, Key ML, Seehra J, Arnett TR, Vanderkerken K, Croucher P. Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo. Journal of Bone and Mineral Research 2010, 25(12):2633-2646. 10.1002/jbmr.142, 20533325.
30. Campbell RA, Sanchez E, Steinberg J, Shalitin D, Li ZW, Chen H, Berenson JR. Vorinostat enhances the antimyeloma effects of melphalan and bortezomib. Eur J Haematol 2010, 84(3):201-211. 10.1111/j.1600-0609.2009.01384.x, 19929977.
31. Sordillo EM, Pearse RN. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma. Cancer 2003, 97(3 Suppl):802-812.
32. Campbell RA, Sanchez E, Steinberg JA, Baritaki S, Gordon M, Wang C, Shalitin D, Chen H, Pang S, Bonavida B, Said J, Berenson JR. Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid. Br J Haematol 2007, 138(4):467-478. 10.1111/j.1365-2141.2007.06675.x, 17587338.
33. Turner RM, Johnson LR, Haig-Ladewig L, Gerton GL, Moss SB. An X-linked gene encodes a major human sperm fibrous sheath protein, hAKAP82. Genomic organization, protein kinase A-RII binding, and distribution of the precursor in the sperm tail. J Biol Chem 1998, 273(48):32135-32141. 10.1074/jbc.273.48.32135, 9822690.
34. Turner RM, Musse MP, Mandal A, Klotz K, Jayes FC, Herr JC, Gerton GL, Moss SB, Chemes HE. Molecular genetic analysis of two human sperm fibrous sheath proteins, AKAP4 and AKAP3, in men with dysplasia of the fibrous sheath. J Androl 2001, 22(2):302-315.
35. Chiriva-Internati M, Cobos E, Da Silva DM, Kast WM. Sperm fibrous sheath proteins: a potential new class of target antigens for use in human therapeutic cancer vaccines. Cancer Immun 2008, 8:8. 2935778, 18433090.
36. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 2002, 188:22-32. 10.1034/j.1600-065X.2002.18803.x, 12445278.
37. Chiriva-Internati M, Ferrari R, Yu Y, Hamrick C, Gagliano N, Grizzi F, Frezza E, Jenkins MR, Hardwick F, D'Cunha N, Kast WM, Cobos E. AKAP-4: a novel cancer testis antigen for multiple myeloma. Br J Haematol 2008, 140(4):465-8. 10.1111/j.1365-2141.2007.06940.x, 18217892.
38. Miyakawa Y, Ohnishi Y, Tomisawa M, Monnai M, Kohmura K, Ueyama Y, Ito M, Ikeda Y, Kizaki M, Nakamura M. Establishment of a new model of human multiple myeloma using NOD/SCID/gammac(null) (NOG) mice. Biochem Biophys Res Commun 2004, 313(2):258-262. 10.1016/j.bbrc.2003.11.120, 14684154.
39. Yaccoby S, Barlogie B, Epstein J. Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood 1998, 92(8):2908-2913.
40. Dutta-Simmons J, Zhang Y, Gorgun G, Gatt M, Mani M, Hideshima T, Takada K, Carlson NE, Carrasco DE, Tai YT, Raje N, Letai AG, Anderson KC, Carrasco DR. Aurora kinase A is a target of Wnt/beta-catenin involved in multiple myeloma disease progression. Blood 2009, 114(13):2699-2708.
41. Azab AK, Runnels JM, Pitsillides C, Moreau AS, Azab F, Leleu X, Jia X, Wright R, Ospina B, Carlson AL, Alt C, Burwick N, Roccaro AM, Ngo HT, Farag M, Melhem MR, Sacco A, Munshi NC, Hideshima T, Rollins BJ, Anderson KC, Kung AL, Lin CP, Ghobrial IM. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 2009, 113(18):4341-4351. 10.1182/blood-2008-10-186668, 2676090, 19139079.
42. Labrinidis A, Diamond P, Martin S, Hay S, Liapis V, Zinonos I, Sims NA, Atkins GJ, Vincent C, Ponomarev V, Findlay DM, Zannettino AC, Evdokiou A. Apo2L/TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myeloma. Clin Cancer Res 2009, 15(6):1998-2009. 10.1158/1078-0432.CCR-08-2444, 19276263.
43. Reijmers RM, Groen RW, Rozemuller H, Kuil A, de Haan-Kramer A, Csikos T, Martens AC, Spaargaren M, Pals ST. Targeting EXT1 reveals a crucial role for heparan sulfate in the growth of multiple myeloma. Blood 2010, 115(3):601-604. 10.1182/blood-2009-02-204396, 19965677.
44. Nakashima T, Ishii T, Tagaya H, Seike T, Nakagawa H, Kanda Y, Akinaga S, Soga S, Shiotsu Y. New molecular and biological mechanism of antitumor activities of KW-2478, a novel nonansamycin heat shock protein 90 inhibitor, in multiple myeloma cells. Clin Cancer Res 2010, 16(10):2792-2802. 10.1158/1078-0432.CCR-09-3112, 20406843.
45. Lavazza C, Carlo-Stella C, Giacomini A, Cleris L, Righi M, Sia D, Di Nicola M, Magni M, Longoni P, Milanesi M, Francolini M, Gloghini A, Carbone A, Formelli F, Gianni AM. Human CD34+ cells engineered to express membrane-bound tumor necrosis factor-related apoptosis-inducing ligand target both tumor cells and tumor vasculature. Blood 2010, 115(11):2231-2240. 10.1182/blood-2009-08-239632, 20075160.
46. Koomen JM, Haura EB, Bepler G, Sutphen R, Remily-Wood ER, Benson K, Hussein M, Hazlehurst LA, Yeatman TJ, Hildreth LT, Sellers TA, Jacobsen PB, Fenstermacher DA, Dalton WS. Proteomic contributions to personalized cancer care. Mol Cell Proteomics 2008, 7(10):1780-1794. 10.1074/mcp.R800002-MCP200, 2559938, 18664563.
47. Yeung J, Chang H. Genomic aberrations and immunohistochemical markers as prognostic indicators in multiple myeloma. J Clin Pathol 2008, 61(7):832-836. 10.1136/jcp.2007.049585, 18077770.
48. Croese JW, Vas Nunes CM, Radl J, van den Enden-Vieveen MH, Brondijk RJ, Boersma WJ. The 5T2 mouse multiple myeloma model: characterization of 5T2 cells within the bone marrow. Br J Cancer 1987, 56(5):555-560. 10.1038/bjc.1987.241, 2001900, 3426918.
49. Vanderkerken K, De Raeve H, Goes E, Van Meirvenne S, Radl J, Van Riet I, Thielemans K, Van Camp B. Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse. Br J Cancer 1997, 76(4):451-460. 10.1038/bjc.1997.409, 2227997, 9275021.
50. Campbell RA, Manyak SJ, Yang HH, Sjak-Shie NN, Chen H, Gui D, Popoviciu L, Wang C, Gordon M, Pang S, Bonavida B, Said J, Berenson JR. LAGlambda-1: a clinically relevant drug resistant human multiple myeloma tumor murine model that enables rapid evaluation of treatments for multiple myeloma. Int J Oncol 2006, 28(6):1409-1417.
51. Kovalchuk AL, Kim JS, Park SS, Coleman AE, Ward JM, Morse HC, Kishimoto T, Potter M, Janz S. IL-6 transgenic mouse model for extraosseous plasmacytoma. Proc Natl Acad Sci USA 2002, 99(3):1509-1514. 10.1073/pnas.022643999, 122221, 11805288.
52. Cheung WC, Kim JS, Linden M, Peng L, Van Ness B, Polakiewicz RD, Janz S. Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice. J Clin Invest 2004, 113(12):1763-1773. 420503, 15199411.
53. Yaccoby S, Epstein J. The proliferative potential of myeloma plasma cells manifest in the SCID-hu host. Blood 1999, 94(10):3576-3582.
54. Yaccoby S, Johnson CL, Mahaffey SC, Wezeman MJ, Barlogie B, Epstein J. Antimyeloma efficacy of thalidomide in the SCID-hu model. Blood 2002, 100(12):4162-4168. 10.1182/blood-2002-03-0939, 12393672.
55. Pearse RN, Sordillo EM, Yaccoby S, Wong BR, Liau DF, Colman N, Michaeli J, Epstein J, Choi Y. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci USA 2001, 98(20):11581-11586. 10.1073/pnas.201394498, 58772, 11562486.
56. Araki K, Sangai T, Miyamoto S, Maeda H, Zhang SC, Nakamura M, Ishii G, Hasebe T, Kusaka H, Akiyama T, Tokuda Y, Nagai K, Minami H, Ochiai A. Inhibition of bone-derived insulin-like growth factors by a ligand-specific antibody suppresses the growth of human multiple myeloma in the human adult bone explanted in NOD/SCID mouse. Int J Cancer 2006, 118(10):2602-2608. 10.1002/ijc.21653, 16353147.
57. Bueno C, Lopes LF, Greaves M, Menendez P. Toward development of a novel NOD/SCID-based in vivo strategy to model multiple myeloma pathogenesis. Exp Hematol 2007, 35(10):1477-8. Epub 2007 Aug 3, 10.1016/j.exphem.2007.06.012, 17681665.
58. van den Akker TW, Radl J, Franken-Postma E, Hagemeijer A. Cytogenetic findings in mouse multiple myeloma and Waldenstrom's macroglobulinemia. Cancer Genet Cytogenet 1996, 86(2):156-161. 10.1016/0165-4608(95)00169-7, 8603345.
59. Radl J, Punt YA, van den Enden-Vieveen MH, Bentvelzen PA, Bakkus MH, van den Akker TW, Benner R. The 5T mouse multiple myeloma model: absence of c-myc oncogene rearrangement in early transplant generations. Br J Cancer 1990, 61(2):276-278. 10.1038/bjc.1990.51, 1971422, 2310679.
60. Fernandes MS, Gomes EM, Butcher LD, Hernandez-Alcoceba R, Chang D, Kansopon J, Newman J, Stone MJ, Tong AW. Growth inhibition of human multiple myeloma cells by an oncolytic adenovirus carrying the CD40 ligand transgene. Clin Cancer Res 2009, 15(15):4847-4856. 10.1158/1078-0432.CCR-09-0451, 19622582.
61. Chauhan D, Singh AV, Aujay M, Kirk CJ, Bandi M, Ciccarelli B, Raje N, Richardson P, Anderson KC. A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood 2010, 116(23):4906-4915. 10.1182/blood-2010-04-276626, 20805366.
62. Singh AV, Bandi M, Aujay MA, Kirk CJ, Hark DE, Raje N, Chauhan D, Anderson KC. PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo. Br J Haematol 2011, 152(2):155-163. 10.1111/j.1365-2141.2010.08491.x, 21114484.
63. Nefedova Y, Landowski TH, Dalton WS. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia 2003, 17(6):1175-1182. 10.1038/sj.leu.2402924, 12764386.
64. Urashima M, Chen BP, Chen S, Pinkus GS, Bronson RT, Dedera DA, Hoshi Y, Teoh G, Ogata A, Treon SP, Chauhan D, Anderson KC. The development of a model for the homing of multiple myeloma cells to human bone marrow. Blood 1997, 90(2):754-765.
65. Barlogie B, Shaughnessy J, Tricot G, Jacobson J, Zangari M, Anaissie E, Walker R, Crowley J. Treatment of multiple myeloma. Blood 2004, 103(1):20-32. 10.1182/blood-2003-04-1045, 12969978.
66. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood 2004, 104(3):607-618. 10.1182/blood-2004-01-0037, 15090448.
67. Steensma DP, Gertz MA, Greipp PR, Kyle RA, Lacy MQ, Lust JA, Offord JR, Plevak MF, Therneau TM, Witzig TE. A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and death. Blood 2001, 97(8):2522-2523. 10.1182/blood.V97.8.2522, 11290618.
68. Vande Broek I, Vanderkerken K, Van Camp B, Van Riet I. Extravasation and homing mechanisms in multiple myeloma. Clin Exp Metastasis 2008, 25(4):325-334. 10.1007/s10585-007-9108-4, 17952614.
69. Moulopoulos LA, Dimopoulos MA, Vourtsi A, Gouliamos A, Vlahos L. Bone lesions with soft-tissue mass: magnetic resonance imaging diagnosis of lymphomatous involvement of the bone marrow versus multiple myeloma and bone metastases. Leuk Lymphoma 1999, 34(1-2):179-184.
70. Santonocito AM, Consoli U, Bagnato S, Milone G, Palumbo GA, Di Raimondo F, Stagno F, Guglielmo P, Giustolisi R. Flow cytometric detection of aneuploid CD38(++) plasmacells and CD19(+) B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients. Leuk Res 2004, 28(5):469-477. 10.1016/j.leukres.2003.09.015, 15068900.
71. Tong WG, Chen R, Plunkett W, Siegel D, Sinha R, Harvey RD, Badros AZ, Popplewell L, Coutre S, Fox JA, Mahadocon K, Chen T, Kegley P, Hoch U, Wierda WG. Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma. J Clin Oncol 2010, 28(18):3015-3022. 10.1200/JCO.2009.26.1347, 20479412.
72. Hall MN, Jagannathan JP, Ramaiya NH, Shinagare AB, Van den Abbeele AD. Imaging of extraosseous myeloma: CT, PET/CT, and MRI features. AJR Am J Roentgenol 2010, 195(5):1057-1065. 10.2214/AJR.10.4384, 20966307.
73. Winterbottom AP, Shaw AS. Imaging patients with myeloma. Clin Radiol 2009, 64(1):1-11. 10.1016/j.crad.2008.07.006, 19070692.
74. Rabin N, Kyriakou C, Coulton L, Gallagher OM, Buckle C, Benjamin R, Singh N, Glassford J, Otsuki T, Nathwani AC, Croucher PI, Yong KL. A new xenograft model of myeloma bone disease demonstrating the efficacy of human mesenchymal stem cells expressing osteoprotegerin by lentiviral gene transfer. Leukemia 2007, 21(10):2181-2191. 10.1038/sj.leu.2404814, 17657224.
75. Gatt ME, Zhao JJ, Ebert MS, Zhang Y, Chu Z, Mani M, Gazit R, Carrasco DE, Dutta-Simmons J, Adamia S, Minvielle S, Tai YT, Munshi NC, Avet-Loiseau H, Anderson KC, Carrasco DR. MicroRNAs 15a/16-1 function as tumor suppressor genes in multiple myeloma. Blood 2010,
76. de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, Oomen LA, Peipp M, Valerius T, Slootstra JW, Mutis T, Bleeker WK, Anderson KC, Lokhorst HM, van de Winkel JG, Parren PW. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 2011, 186(3):1840-1848. 10.4049/jimmunol.1003032, 21187443.
77. Lim SH, Wang Z, Chiriva-Internati M, Xue Y. Sperm protein 17 is a novel cancer-testis antigen in multiple myeloma. Blood 2001, 97(5):1508-1510. 10.1182/blood.V97.5.1508, 11222401.
78. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979, 76(9):4350-4354. 10.1073/pnas.76.9.4350, 411572, 388439.